Source comparison
BPC-157 Studied SIBO: Comparison of Treatment Mechanisms
Rifaximin (antibiotic) Inhibits bacterial RNA synthesis. Non-absorbable, targets small intestine Phase III human trials, FDA-approved for IBS-D with SIBO 10–14 days 60–70% reduction (breath test normalization) None. May worsen if dysbiosis develops Gold standa
This comparison does not assign a generated winner or score.
- Rifaximin (antibiotic)
- Inhibits bacterial RNA synthesis. Non-absorbable, targets small intestine
- Phase III human trials, FDA-approved for IBS-D with SIBO
- 10–14 days
- 60–70% reduction (breath test normalization)
- None. May worsen if dysbiosis develops
- Gold standard for bacterial eradication, no healing component
- BPC-157 (peptide)
- Mucosal repair via VEGF upregulation, motility modulation, tight junction restoration
- Preclinical only. No human SIBO trials
- Unknown in humans (7–14 days in animal models)
- Not directly measured. Proposed via motility improvement
- Strong in animal models (68% permeability reduction)
- Mechanistically plausible but clinically unvalidated for SIBO
- Prokinetics (e.g., prucalopride)
- 5-HT4 receptor agonist. Stimulates MMC cycling
- Human studies for chronic constipation, not SIBO-specific
- 3–7 days for motility improvement
- Indirect. Prevents recurrence, doesn't eradicate existing overgrowth
- None
- Addresses root cause (motility failure) but requires concurrent antimicrobial for active SIBO
- Herbal antimicrobials (berberine, oregano oil)
- Broad-spectrum antibacterial via multiple pathways
- Small human trials, comparable efficacy to rifaximin in one 2014 study
- 14–30 days
- 46% breath test normalization (Johns Hopkins study)
- Minimal. Berberine has mild anti-inflammatory effects
- Less potent than rifaximin, useful for rifaximin-refractory cases